Depixus

The company is focused on commercializing its proprietary MAGNA™ platform, a laboratory instrument system designed for the high-throughput analysis of biomolecular interactions at the single-molecule level. The core technology, magnetic force spectroscopy, involves attaching a magnetic bead to individual molecules like DNA, RNA, or proteins. A magnetic field is then used to apply force to these beads, allowing researchers to observe the dynamics of interactions in real-time, such as a drug binding to an RNA molecule or proteins interacting with each other. This method provides detailed data on binding strength, kinetics, and molecular structure that is often lost in traditional bulk analysis techniques.

Depixus operates on a business model centered on selling its MAGNA One instrument, along with associated workflows and reagents, to research laboratories in the biopharmaceutical industry and academia. The technology serves researchers aiming to decode disease mechanisms and accelerate drug discovery, particularly for challenging targets like RNA and protein-protein interactions. The platform's ability to provide high-resolution data on individual molecular events helps scientists differentiate biological signals from analytical noise, which can reduce costly failures in preclinical and clinical drug development. The company has secured over €50 million in funding through a combination of equity financing and grants. A significant Series A round in December 2021 raised €30.6 million, co-led by Lansdowne Partners and Bpifrance, to advance the MAGNA system towards commercial launch.